 Jay Portnoy
Concepts (535)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 65 | 2023 | 152 | 16.400 |
Why?
| | Telemedicine | 25 | 2023 | 59 | 13.900 |
Why?
| | Hypersensitivity | 47 | 2024 | 56 | 13.780 |
Why?
| | Allergens | 56 | 2023 | 58 | 9.010 |
Why?
| | Humans | 196 | 2024 | 6929 | 6.280 |
Why?
| | Fungi | 18 | 2019 | 20 | 4.970 |
Why?
| | Environmental Exposure | 21 | 2019 | 29 | 4.340 |
Why?
| | Air Pollution, Indoor | 20 | 2023 | 20 | 4.030 |
Why?
| | Anaphylaxis | 9 | 2024 | 10 | 3.670 |
Why?
| | Artificial Intelligence | 5 | 2024 | 14 | 3.200 |
Why?
| | Food Hypersensitivity | 9 | 2021 | 17 | 3.060 |
Why?
| | Peanut Hypersensitivity | 6 | 2023 | 7 | 2.900 |
Why?
| | Allergy and Immunology | 11 | 2022 | 11 | 2.870 |
Why?
| | Adrenal Cortex Hormones | 10 | 2021 | 37 | 2.850 |
Why?
| | Desensitization, Immunologic | 18 | 2023 | 19 | 2.590 |
Why?
| | Pollen | 10 | 2019 | 10 | 2.370 |
Why?
| | Child | 57 | 2023 | 3348 | 2.260 |
Why?
| | Anti-Asthmatic Agents | 7 | 2023 | 11 | 2.220 |
Why?
| | Air Pollutants | 10 | 2023 | 12 | 2.190 |
Why?
| | Rhinitis, Allergic | 5 | 2023 | 10 | 2.120 |
Why?
| | Rhinitis, Allergic, Seasonal | 15 | 2019 | 15 | 2.120 |
Why?
| | Pandemics | 8 | 2023 | 81 | 1.990 |
Why?
| | Practice Guidelines as Topic | 18 | 2020 | 104 | 1.990 |
Why?
| | Epinephrine | 6 | 2024 | 7 | 1.510 |
Why?
| | Hypersensitivity, Immediate | 7 | 2013 | 7 | 1.490 |
Why?
| | Arachis | 5 | 2023 | 5 | 1.420 |
Why?
| | Child, Preschool | 31 | 2022 | 1562 | 1.400 |
Why?
| | United States | 17 | 2019 | 670 | 1.360 |
Why?
| | Immunoglobulin E | 15 | 2023 | 22 | 1.350 |
Why?
| | Adolescent | 33 | 2023 | 2183 | 1.300 |
Why?
| | Delivery of Health Care | 4 | 2023 | 33 | 1.300 |
Why?
| | Patient Education as Topic | 13 | 2019 | 53 | 1.270 |
Why?
| | Alternaria | 12 | 2014 | 12 | 1.260 |
Why?
| | Female | 36 | 2020 | 3534 | 1.240 |
Why?
| | Immunotherapy | 7 | 2022 | 16 | 1.220 |
Why?
| | Algorithms | 7 | 2024 | 108 | 1.190 |
Why?
| | Male | 34 | 2020 | 3367 | 1.170 |
Why?
| | Skin Tests | 16 | 2020 | 19 | 1.170 |
Why?
| | Pediatrics | 2 | 2019 | 183 | 1.170 |
Why?
| | Environmental Monitoring | 6 | 2013 | 6 | 1.140 |
Why?
| | Patient Satisfaction | 7 | 2022 | 44 | 1.130 |
Why?
| | Animals | 20 | 2017 | 741 | 1.120 |
Why?
| | Monitoring, Physiologic | 3 | 2023 | 23 | 1.100 |
Why?
| | Rhinitis, Allergic, Perennial | 8 | 2013 | 10 | 1.080 |
Why?
| | Coronavirus Infections | 3 | 2020 | 15 | 1.070 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 16 | 1.070 |
Why?
| | Dust | 9 | 2016 | 9 | 1.020 |
Why?
| | Diagnostic Tests, Routine | 2 | 2021 | 19 | 0.990 |
Why?
| | Machine Learning | 1 | 2024 | 17 | 0.970 |
Why?
| | Spores | 6 | 2006 | 6 | 0.940 |
Why?
| | Health Services Accessibility | 3 | 2019 | 38 | 0.940 |
Why?
| | Bayes Theorem | 2 | 2021 | 30 | 0.930 |
Why?
| | Housing | 8 | 2017 | 11 | 0.910 |
Why?
| | Air Microbiology | 5 | 2017 | 5 | 0.900 |
Why?
| | Authorship | 1 | 2023 | 3 | 0.900 |
Why?
| | Stachybotrys | 4 | 2017 | 4 | 0.890 |
Why?
| | Remote Consultation | 2 | 2020 | 4 | 0.880 |
Why?
| | Bronchodilator Agents | 4 | 2019 | 11 | 0.870 |
Why?
| | Fungal Proteins | 7 | 2013 | 10 | 0.860 |
Why?
| | Histamine Antagonists | 4 | 2020 | 8 | 0.860 |
Why?
| | Antigens, Dermatophagoides | 3 | 2013 | 3 | 0.840 |
Why?
| | Adrenergic beta-Agonists | 2 | 2014 | 5 | 0.830 |
Why?
| | Rural Population | 2 | 2019 | 41 | 0.830 |
Why?
| | Physicians | 1 | 2022 | 24 | 0.830 |
Why?
| | Spores, Fungal | 7 | 2019 | 7 | 0.820 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 39 | 0.820 |
Why?
| | Likelihood Functions | 2 | 2020 | 6 | 0.800 |
Why?
| | Antigens, Fungal | 9 | 2017 | 10 | 0.800 |
Why?
| | Health Personnel | 2 | 2020 | 24 | 0.760 |
Why?
| | Cell Count | 2 | 2019 | 16 | 0.760 |
Why?
| | Self Care | 3 | 2017 | 22 | 0.760 |
Why?
| | Evidence-Based Medicine | 9 | 2020 | 45 | 0.750 |
Why?
| | Mycotoxins | 3 | 2017 | 3 | 0.750 |
Why?
| | Immunity, Innate | 3 | 2017 | 16 | 0.740 |
Why?
| | Specialization | 2 | 2019 | 7 | 0.730 |
Why?
| | Sublingual Immunotherapy | 2 | 2017 | 2 | 0.730 |
Why?
| | Drug Hypersensitivity | 3 | 2019 | 19 | 0.720 |
Why?
| | Disease Management | 6 | 2019 | 36 | 0.700 |
Why?
| | Latex Hypersensitivity | 2 | 2019 | 2 | 0.700 |
Why?
| | Insect Bites and Stings | 7 | 2019 | 7 | 0.690 |
Why?
| | Education, Medical | 1 | 2019 | 3 | 0.690 |
Why?
| | Education, Distance | 1 | 2019 | 6 | 0.680 |
Why?
| | Injections, Intramuscular | 1 | 2019 | 5 | 0.680 |
Why?
| | Pyroglyphidae | 3 | 2013 | 3 | 0.670 |
Why?
| | Environmental Restoration and Remediation | 2 | 2009 | 2 | 0.650 |
Why?
| | Disinfectants | 2 | 2008 | 2 | 0.650 |
Why?
| | Sodium Hypochlorite | 2 | 2008 | 2 | 0.650 |
Why?
| | Angioedema | 2 | 2015 | 2 | 0.640 |
Why?
| | Cockroaches | 3 | 2013 | 3 | 0.620 |
Why?
| | Peptides | 2 | 2015 | 11 | 0.610 |
Why?
| | Drug Approval | 2 | 2019 | 2 | 0.600 |
Why?
| | Diet Therapy | 2 | 2016 | 3 | 0.590 |
Why?
| | Smartphone | 1 | 2017 | 6 | 0.590 |
Why?
| | Antibodies, Anti-Idiotypic | 2 | 2015 | 3 | 0.580 |
Why?
| | Models, Theoretical | 2 | 2015 | 13 | 0.570 |
Why?
| | Administration, Oral | 7 | 2023 | 58 | 0.570 |
Why?
| | Hospitalization | 2 | 2010 | 209 | 0.560 |
Why?
| | Quality of Life | 5 | 2019 | 139 | 0.560 |
Why?
| | Respiratory Tract Diseases | 2 | 2007 | 8 | 0.550 |
Why?
| | Physician's Role | 2 | 2008 | 7 | 0.550 |
Why?
| | Tranexamic Acid | 1 | 2015 | 1 | 0.530 |
Why?
| | Bradykinin | 1 | 2015 | 5 | 0.530 |
Why?
| | Cetirizine | 3 | 2004 | 4 | 0.530 |
Why?
| | Nebulizers and Vaporizers | 6 | 2021 | 8 | 0.520 |
Why?
| | Respiratory Hypersensitivity | 5 | 2008 | 6 | 0.520 |
Why?
| | Patient Compliance | 3 | 2010 | 56 | 0.520 |
Why?
| | Adult | 12 | 2020 | 1199 | 0.510 |
Why?
| | School Health Services | 1 | 2014 | 9 | 0.490 |
Why?
| | Immune System Diseases | 1 | 2014 | 6 | 0.490 |
Why?
| | Referral and Consultation | 3 | 2019 | 32 | 0.490 |
Why?
| | Administration, Inhalation | 6 | 2023 | 19 | 0.490 |
Why?
| | Emergency Service, Hospital | 3 | 2022 | 129 | 0.480 |
Why?
| | Anti-Allergic Agents | 3 | 2004 | 6 | 0.480 |
Why?
| | Videoconferencing | 3 | 2019 | 5 | 0.470 |
Why?
| | Case Management | 3 | 2010 | 3 | 0.460 |
Why?
| | Treatment Outcome | 10 | 2012 | 649 | 0.440 |
Why?
| | Emergency Medical Services | 2 | 2010 | 15 | 0.440 |
Why?
| | Medication Adherence | 1 | 2012 | 21 | 0.430 |
Why?
| | Severity of Illness Index | 6 | 2019 | 148 | 0.430 |
Why?
| | Complex Mixtures | 1 | 2012 | 1 | 0.430 |
Why?
| | Parent-Child Relations | 1 | 2012 | 36 | 0.430 |
Why?
| | Pets | 1 | 2012 | 1 | 0.420 |
Why?
| | Serologic Tests | 1 | 2011 | 3 | 0.400 |
Why?
| | Counseling | 2 | 2009 | 26 | 0.400 |
Why?
| | Practice Patterns, Physicians' | 3 | 2013 | 85 | 0.400 |
Why?
| | Antibodies, Monoclonal | 4 | 2006 | 23 | 0.380 |
Why?
| | Dermatitis, Atopic | 5 | 2013 | 7 | 0.370 |
Why?
| | Community Health Services | 2 | 2010 | 7 | 0.370 |
Why?
| | Immunization | 3 | 2020 | 25 | 0.370 |
Why?
| | Decision Making, Computer-Assisted | 2 | 2020 | 2 | 0.360 |
Why?
| | Air Pollution | 2 | 2019 | 4 | 0.360 |
Why?
| | Health Maintenance Organizations | 1 | 2009 | 1 | 0.340 |
Why?
| | Family Practice | 1 | 2009 | 4 | 0.340 |
Why?
| | School Nursing | 1 | 2009 | 5 | 0.340 |
Why?
| | Time Factors | 7 | 2019 | 263 | 0.330 |
Why?
| | Environmental Illness | 2 | 2007 | 2 | 0.330 |
Why?
| | Status Asthmaticus | 2 | 2003 | 2 | 0.330 |
Why?
| | Risk Assessment | 3 | 2019 | 136 | 0.320 |
Why?
| | Age Factors | 5 | 2019 | 211 | 0.320 |
Why?
| | Clinical Trials as Topic | 5 | 2016 | 44 | 0.310 |
Why?
| | Missouri | 6 | 2017 | 77 | 0.310 |
Why?
| | Schools | 2 | 2020 | 56 | 0.300 |
Why?
| | Guideline Adherence | 3 | 2010 | 34 | 0.300 |
Why?
| | Humidity | 1 | 2007 | 3 | 0.300 |
Why?
| | Histamine H1 Antagonists, Non-Sedating | 2 | 2004 | 3 | 0.290 |
Why?
| | Meteorological Concepts | 2 | 2004 | 3 | 0.290 |
Why?
| | Colony Count, Microbial | 4 | 2014 | 4 | 0.290 |
Why?
| | Vaccines | 4 | 2012 | 17 | 0.290 |
Why?
| | Infant | 10 | 2016 | 1449 | 0.290 |
Why?
| | Terfenadine | 2 | 2003 | 2 | 0.280 |
Why?
| | Government Programs | 1 | 2006 | 4 | 0.280 |
Why?
| | Health Plan Implementation | 1 | 2006 | 9 | 0.280 |
Why?
| | Medical History Taking | 2 | 2003 | 4 | 0.280 |
Why?
| | Surveys and Questionnaires | 3 | 2023 | 275 | 0.270 |
Why?
| | Life Style | 1 | 2006 | 24 | 0.270 |
Why?
| | Asthma, Exercise-Induced | 3 | 2016 | 3 | 0.270 |
Why?
| | Program Evaluation | 3 | 2019 | 45 | 0.270 |
Why?
| | Prevalence | 5 | 2016 | 150 | 0.260 |
Why?
| | Middle Aged | 4 | 2019 | 645 | 0.260 |
Why?
| | Seasons | 3 | 2011 | 35 | 0.260 |
Why?
| | Insurance, Health | 2 | 2019 | 17 | 0.250 |
Why?
| | Histamine H1 Antagonists | 1 | 2004 | 5 | 0.250 |
Why?
| | Family Health | 1 | 2004 | 14 | 0.250 |
Why?
| | Tobacco Smoke Pollution | 2 | 2014 | 5 | 0.240 |
Why?
| | Immunoenzyme Techniques | 3 | 2006 | 9 | 0.240 |
Why?
| | Precision Medicine | 1 | 2024 | 43 | 0.240 |
Why?
| | Immunoblotting | 4 | 2002 | 11 | 0.230 |
Why?
| | Sleep Stages | 1 | 2003 | 1 | 0.230 |
Why?
| | Arthropod Venoms | 2 | 2019 | 2 | 0.230 |
Why?
| | Information Services | 1 | 2003 | 1 | 0.230 |
Why?
| | Antigens, Plant | 3 | 2017 | 3 | 0.230 |
Why?
| | Diagnosis, Computer-Assisted | 1 | 2023 | 4 | 0.230 |
Why?
| | Double-Blind Method | 7 | 2020 | 45 | 0.220 |
Why?
| | Powders | 1 | 2023 | 1 | 0.220 |
Why?
| | Single-Blind Method | 3 | 2009 | 14 | 0.220 |
Why?
| | Plant Proteins | 2 | 2018 | 3 | 0.220 |
Why?
| | Documentation | 1 | 2022 | 7 | 0.210 |
Why?
| | Injections, Subcutaneous | 1 | 2022 | 8 | 0.210 |
Why?
| | Phobic Disorders | 1 | 2022 | 4 | 0.210 |
Why?
| | Attitude | 1 | 2022 | 10 | 0.210 |
Why?
| | Hospitals, Pediatric | 1 | 2003 | 186 | 0.210 |
Why?
| | Chronic Disease | 2 | 2020 | 106 | 0.200 |
Why?
| | Poaceae | 2 | 2017 | 2 | 0.200 |
Why?
| | Trees | 2 | 2017 | 2 | 0.200 |
Why?
| | Climate | 2 | 2019 | 4 | 0.200 |
Why?
| | Antibodies, Fungal | 3 | 2017 | 3 | 0.200 |
Why?
| | Mass Screening | 1 | 2021 | 34 | 0.200 |
Why?
| | Bronchiolitis, Viral | 2 | 1993 | 4 | 0.190 |
Why?
| | Nomograms | 1 | 2020 | 1 | 0.180 |
Why?
| | ROC Curve | 1 | 2020 | 21 | 0.180 |
Why?
| | Adaptive Immunity | 2 | 2017 | 5 | 0.180 |
Why?
| | Videotape Recording | 1 | 2020 | 3 | 0.180 |
Why?
| | Triage | 1 | 2020 | 6 | 0.180 |
Why?
| | Urticaria | 2 | 2014 | 2 | 0.180 |
Why?
| | Retrospective Studies | 6 | 2014 | 1337 | 0.180 |
Why?
| | Cross-Sectional Studies | 2 | 2019 | 333 | 0.180 |
Why?
| | General Practice | 1 | 2019 | 1 | 0.180 |
Why?
| | Immunologic Deficiency Syndromes | 2 | 2020 | 8 | 0.180 |
Why?
| | Nasal Obstruction | 2 | 2017 | 3 | 0.180 |
Why?
| | Lymphoma, T-Cell | 1 | 2019 | 2 | 0.180 |
Why?
| | Ambulatory Care Facilities | 1 | 2020 | 37 | 0.180 |
Why?
| | Glucocorticoids | 1 | 2020 | 31 | 0.180 |
Why?
| | Patient Participation | 1 | 2019 | 15 | 0.180 |
Why?
| | Asparaginase | 1 | 2019 | 12 | 0.180 |
Why?
| | Polyethylene Glycols | 1 | 2019 | 9 | 0.180 |
Why?
| | Aged | 2 | 2019 | 411 | 0.170 |
Why?
| | Young Adult | 2 | 2019 | 641 | 0.170 |
Why?
| | Computer-Assisted Instruction | 1 | 2019 | 3 | 0.170 |
Why?
| | Congresses as Topic | 1 | 2019 | 9 | 0.170 |
Why?
| | User-Computer Interface | 1 | 2019 | 11 | 0.170 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 16 | 0.170 |
Why?
| | Cost-Benefit Analysis | 1 | 2019 | 27 | 0.170 |
Why?
| | Self Administration | 1 | 2019 | 2 | 0.170 |
Why?
| | Curriculum | 1 | 2019 | 22 | 0.170 |
Why?
| | Drug Combinations | 1 | 2019 | 20 | 0.170 |
Why?
| | Self Concept | 1 | 2019 | 8 | 0.170 |
Why?
| | Family Characteristics | 1 | 2019 | 9 | 0.170 |
Why?
| | Mitosporic Fungi | 2 | 1990 | 2 | 0.170 |
Why?
| | Weather | 1 | 2019 | 4 | 0.170 |
Why?
| | Climate Change | 1 | 2019 | 2 | 0.170 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 56 | 0.170 |
Why?
| | Educational Status | 1 | 2019 | 21 | 0.170 |
Why?
| | Income | 1 | 2019 | 17 | 0.170 |
Why?
| | Multivariate Analysis | 1 | 2019 | 73 | 0.170 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2019 | 50 | 0.170 |
Why?
| | Biological Products | 1 | 2018 | 3 | 0.170 |
Why?
| | Longitudinal Studies | 1 | 2019 | 119 | 0.170 |
Why?
| | Penicillin G | 1 | 2018 | 1 | 0.170 |
Why?
| | Penicillins | 1 | 2018 | 8 | 0.160 |
Why?
| | Licensure, Medical | 1 | 2018 | 1 | 0.160 |
Why?
| | Medical Staff Privileges | 1 | 2018 | 1 | 0.160 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 6 | 1996 | 24 | 0.160 |
Why?
| | Respiratory Function Tests | 3 | 2006 | 16 | 0.160 |
Why?
| | Consensus | 2 | 2023 | 33 | 0.160 |
Why?
| | Mycoses | 3 | 2006 | 12 | 0.160 |
Why?
| | Temperature | 2 | 2011 | 12 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 4 | 2017 | 57 | 0.160 |
Why?
| | Advisory Committees | 2 | 2015 | 9 | 0.160 |
Why?
| | Cats | 2 | 2012 | 4 | 0.150 |
Why?
| | RNA, Messenger | 1 | 1998 | 115 | 0.150 |
Why?
| | Dogs | 2 | 2012 | 28 | 0.150 |
Why?
| | Pathogen-Associated Molecular Pattern Molecules | 1 | 2017 | 1 | 0.150 |
Why?
| | Receptors, Pattern Recognition | 1 | 2017 | 1 | 0.150 |
Why?
| | Particulate Matter | 1 | 2017 | 1 | 0.150 |
Why?
| | Risk Factors | 3 | 2020 | 490 | 0.150 |
Why?
| | Cities | 1 | 2017 | 10 | 0.150 |
Why?
| | Venoms | 1 | 2017 | 2 | 0.150 |
Why?
| | Reproducibility of Results | 3 | 2015 | 198 | 0.150 |
Why?
| | Injections | 1 | 2017 | 5 | 0.150 |
Why?
| | Glycoproteins | 2 | 2013 | 9 | 0.140 |
Why?
| | Bronchoconstriction | 1 | 2016 | 1 | 0.140 |
Why?
| | Follow-Up Studies | 2 | 2009 | 329 | 0.140 |
Why?
| | Patient Safety | 1 | 2016 | 20 | 0.140 |
Why?
| | Recombinant Fusion Proteins | 1 | 1996 | 14 | 0.140 |
Why?
| | Diagnosis, Differential | 4 | 2010 | 78 | 0.130 |
Why?
| | Societies, Medical | 2 | 2014 | 50 | 0.130 |
Why?
| | Socioeconomic Factors | 3 | 2015 | 53 | 0.130 |
Why?
| | Bacteria | 1 | 2015 | 9 | 0.130 |
Why?
| | Antibodies | 2 | 1993 | 16 | 0.130 |
Why?
| | Poverty | 1 | 2015 | 25 | 0.130 |
Why?
| | Dermatitis, Contact | 1 | 2015 | 1 | 0.130 |
Why?
| | Rhinitis | 2 | 2008 | 3 | 0.130 |
Why?
| | Ambulatory Care | 1 | 2015 | 45 | 0.130 |
Why?
| | Terbutaline | 2 | 2020 | 2 | 0.130 |
Why?
| | Patient Care Planning | 1 | 2014 | 1 | 0.120 |
Why?
| | Sympathomimetics | 1 | 2014 | 2 | 0.120 |
Why?
| | Infant, Newborn | 2 | 2016 | 826 | 0.120 |
Why?
| | Adrenergic beta-2 Receptor Agonists | 1 | 2014 | 1 | 0.120 |
Why?
| | Immunologic Techniques | 1 | 2014 | 2 | 0.120 |
Why?
| | Drug Therapy, Combination | 2 | 2017 | 37 | 0.120 |
Why?
| | Caregivers | 1 | 2014 | 38 | 0.120 |
Why?
| | Primary Prevention | 1 | 2013 | 2 | 0.120 |
Why?
| | Vaccination | 2 | 2012 | 70 | 0.120 |
Why?
| | Spirometry | 3 | 2008 | 6 | 0.120 |
Why?
| | Interferon-alpha | 1 | 1993 | 2 | 0.120 |
Why?
| | Sensitivity and Specificity | 2 | 2011 | 151 | 0.110 |
Why?
| | Hereditary Angioedema Types I and II | 1 | 2013 | 1 | 0.110 |
Why?
| | Risk | 3 | 2019 | 42 | 0.110 |
Why?
| | Respiratory Syncytial Virus, Human | 1 | 1993 | 27 | 0.110 |
Why?
| | Recombinant Proteins | 2 | 2008 | 52 | 0.110 |
Why?
| | Disease Reservoirs | 1 | 2012 | 1 | 0.110 |
Why?
| | Food Contamination | 1 | 2012 | 1 | 0.110 |
Why?
| | Pest Control | 1 | 2012 | 1 | 0.110 |
Why?
| | Rodentia | 1 | 2012 | 1 | 0.110 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 1993 | 50 | 0.110 |
Why?
| | Health Care Costs | 2 | 2010 | 31 | 0.110 |
Why?
| | Prognosis | 2 | 2019 | 216 | 0.110 |
Why?
| | United States Food and Drug Administration | 1 | 2012 | 7 | 0.110 |
Why?
| | Sneezing | 3 | 2009 | 3 | 0.110 |
Why?
| | Expert Testimony | 1 | 2012 | 3 | 0.100 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1992 | 2 | 0.100 |
Why?
| | Observer Variation | 2 | 2002 | 14 | 0.100 |
Why?
| | Urban Population | 2 | 2015 | 27 | 0.100 |
Why?
| | Methotrexate | 1 | 1992 | 28 | 0.100 |
Why?
| | Kansas | 3 | 2014 | 43 | 0.100 |
Why?
| | Adjuvants, Immunologic | 2 | 2008 | 3 | 0.100 |
Why?
| | Carbohydrates | 1 | 1991 | 2 | 0.100 |
Why?
| | Ambrosia | 1 | 2011 | 1 | 0.100 |
Why?
| | Quality Assurance, Health Care | 2 | 2017 | 6 | 0.100 |
Why?
| | Parents | 1 | 2012 | 152 | 0.100 |
Why?
| | Egg Hypersensitivity | 1 | 2011 | 2 | 0.100 |
Why?
| | Administration, Intranasal | 4 | 2017 | 8 | 0.090 |
Why?
| | Decision Making | 2 | 2015 | 23 | 0.090 |
Why?
| | Aerosols | 2 | 2003 | 4 | 0.090 |
Why?
| | Influenza Vaccines | 1 | 2011 | 26 | 0.090 |
Why?
| | Health Planning Guidelines | 1 | 2010 | 2 | 0.090 |
Why?
| | Managed Care Programs | 1 | 2010 | 3 | 0.090 |
Why?
| | Quality Control | 2 | 2000 | 8 | 0.090 |
Why?
| | Phthalazines | 1 | 2009 | 1 | 0.090 |
Why?
| | Sucrose | 1 | 2009 | 1 | 0.090 |
Why?
| | Sweetening Agents | 1 | 2009 | 1 | 0.090 |
Why?
| | Candidiasis, Chronic Mucocutaneous | 1 | 1989 | 1 | 0.090 |
Why?
| | Candidiasis | 1 | 1989 | 5 | 0.090 |
Why?
| | Air Conditioning | 1 | 2009 | 1 | 0.090 |
Why?
| | Comparative Effectiveness Research | 1 | 2009 | 6 | 0.090 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 3 | 1993 | 9 | 0.090 |
Why?
| | Cooperative Behavior | 1 | 2009 | 24 | 0.080 |
Why?
| | Vaccines, DNA | 1 | 2008 | 1 | 0.080 |
Why?
| | Bacterial Vaccines | 1 | 2008 | 2 | 0.080 |
Why?
| | Registries | 1 | 2009 | 93 | 0.080 |
Why?
| | Program Development | 2 | 2010 | 12 | 0.080 |
Why?
| | Respirovirus Infections | 1 | 1988 | 1 | 0.080 |
Why?
| | Ergosterol | 1 | 2008 | 1 | 0.080 |
Why?
| | Glucans | 1 | 2008 | 1 | 0.080 |
Why?
| | Irritants | 1 | 2008 | 1 | 0.080 |
Why?
| | Interferon Type I | 1 | 1988 | 5 | 0.080 |
Why?
| | Albuterol | 3 | 2020 | 5 | 0.080 |
Why?
| | Antibody Specificity | 2 | 2001 | 8 | 0.080 |
Why?
| | Allied Health Personnel | 1 | 2007 | 1 | 0.080 |
Why?
| | Sick Building Syndrome | 1 | 2007 | 1 | 0.070 |
Why?
| | Blotting, Northern | 2 | 1998 | 5 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 1 | 2008 | 226 | 0.070 |
Why?
| | Molecular Sequence Data | 2 | 1998 | 78 | 0.070 |
Why?
| | Base Sequence | 2 | 1998 | 87 | 0.070 |
Why?
| | Immunoglobulin G | 2 | 2002 | 34 | 0.070 |
Why?
| | Patient Selection | 2 | 2010 | 34 | 0.070 |
Why?
| | Massachusetts | 1 | 2006 | 2 | 0.070 |
Why?
| | Community-Institutional Relations | 1 | 2006 | 5 | 0.070 |
Why?
| | Social Work | 1 | 2006 | 3 | 0.070 |
Why?
| | Research Support as Topic | 1 | 2006 | 5 | 0.070 |
Why?
| | Patient Admission | 1 | 2006 | 10 | 0.070 |
Why?
| | Health Services Needs and Demand | 1 | 2006 | 15 | 0.070 |
Why?
| | Leukotriene Antagonists | 2 | 2017 | 6 | 0.070 |
Why?
| | Drug Utilization | 1 | 2006 | 13 | 0.070 |
Why?
| | Psychophysiologic Disorders | 1 | 1986 | 3 | 0.070 |
Why?
| | Aspergillus | 2 | 2017 | 2 | 0.070 |
Why?
| | Cladosporium | 2 | 2017 | 2 | 0.070 |
Why?
| | Penicillium | 2 | 2017 | 2 | 0.070 |
Why?
| | Mice, Inbred BALB C | 2 | 1998 | 25 | 0.070 |
Why?
| | Bronchoalveolar Lavage | 1 | 2006 | 2 | 0.070 |
Why?
| | Early Diagnosis | 1 | 2006 | 17 | 0.070 |
Why?
| | Sinusitis | 1 | 2005 | 5 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2006 | 47 | 0.070 |
Why?
| | Air | 1 | 2005 | 2 | 0.070 |
Why?
| | Health Status | 1 | 2005 | 25 | 0.060 |
Why?
| | Decontamination | 1 | 2005 | 1 | 0.060 |
Why?
| | Cerebrospinal Fluid | 1 | 1985 | 8 | 0.060 |
Why?
| | Mice | 2 | 1998 | 339 | 0.060 |
Why?
| | Attitude to Health | 1 | 2004 | 27 | 0.060 |
Why?
| | Patient-Centered Care | 1 | 2004 | 16 | 0.060 |
Why?
| | Mycology | 1 | 2004 | 2 | 0.060 |
Why?
| | Product Surveillance, Postmarketing | 1 | 2004 | 1 | 0.060 |
Why?
| | Conditioning, Operant | 1 | 2003 | 2 | 0.060 |
Why?
| | Costs and Cost Analysis | 1 | 2003 | 5 | 0.060 |
Why?
| | Delphi Technique | 1 | 2023 | 11 | 0.060 |
Why?
| | Health Resources | 1 | 2003 | 16 | 0.060 |
Why?
| | Automobile Driving | 1 | 2003 | 5 | 0.060 |
Why?
| | Clinical Decision-Making | 1 | 2023 | 19 | 0.060 |
Why?
| | Drug Prescriptions | 1 | 2003 | 20 | 0.060 |
Why?
| | Particle Size | 1 | 2003 | 2 | 0.060 |
Why?
| | Prednisone | 2 | 1994 | 12 | 0.060 |
Why?
| | Forecasting | 1 | 2023 | 24 | 0.060 |
Why?
| | Hospital Costs | 1 | 2003 | 31 | 0.060 |
Why?
| | False Negative Reactions | 1 | 2003 | 10 | 0.060 |
Why?
| | False Positive Reactions | 1 | 2003 | 4 | 0.060 |
Why?
| | Attitude of Health Personnel | 1 | 2003 | 43 | 0.060 |
Why?
| | Public Health | 1 | 2003 | 19 | 0.060 |
Why?
| | Occupational Exposure | 1 | 2003 | 1 | 0.060 |
Why?
| | Predictive Value of Tests | 1 | 2003 | 102 | 0.060 |
Why?
| | Databases, Factual | 1 | 2003 | 108 | 0.060 |
Why?
| | Emergencies | 1 | 2003 | 11 | 0.050 |
Why?
| | Alkaline Phosphatase | 2 | 1993 | 18 | 0.050 |
Why?
| | Military Medicine | 1 | 2002 | 1 | 0.050 |
Why?
| | Insurance Selection Bias | 1 | 2002 | 1 | 0.050 |
Why?
| | Bronchial Hyperreactivity | 1 | 2002 | 7 | 0.050 |
Why?
| | Airway Obstruction | 1 | 2002 | 16 | 0.050 |
Why?
| | Unnecessary Procedures | 1 | 2002 | 14 | 0.050 |
Why?
| | Medicine | 1 | 2002 | 10 | 0.050 |
Why?
| | Molecular Weight | 1 | 2002 | 2 | 0.050 |
Why?
| | Insurance Coverage | 1 | 2002 | 22 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2023 | 65 | 0.050 |
Why?
| | Recurrence | 1 | 2002 | 121 | 0.050 |
Why?
| | Drug Administration Routes | 1 | 2001 | 3 | 0.050 |
Why?
| | Time | 1 | 2001 | 7 | 0.050 |
Why?
| | Animals, Domestic | 1 | 2001 | 1 | 0.050 |
Why?
| | Mites | 1 | 2001 | 1 | 0.050 |
Why?
| | Inhalation Exposure | 1 | 2001 | 1 | 0.050 |
Why?
| | Insect Proteins | 1 | 2001 | 2 | 0.050 |
Why?
| | Species Specificity | 1 | 2001 | 10 | 0.050 |
Why?
| | Immunoassay | 1 | 2001 | 10 | 0.050 |
Why?
| | Anti-Bacterial Agents | 3 | 2004 | 243 | 0.050 |
Why?
| | Conjunctivitis | 1 | 2001 | 1 | 0.050 |
Why?
| | Biomedical Technology | 1 | 2021 | 5 | 0.050 |
Why?
| | Urban Health | 1 | 2001 | 3 | 0.050 |
Why?
| | Physical Examination | 1 | 2001 | 5 | 0.050 |
Why?
| | Circadian Rhythm | 1 | 2001 | 7 | 0.050 |
Why?
| | Pregnancy | 1 | 2001 | 212 | 0.050 |
Why?
| | Pilot Projects | 2 | 1992 | 114 | 0.040 |
Why?
| | Hemorrhage | 1 | 1999 | 22 | 0.040 |
Why?
| | Lung Diseases | 1 | 1999 | 23 | 0.040 |
Why?
| | Nasal Mucosa | 2 | 2003 | 8 | 0.040 |
Why?
| | Dose-Response Relationship, Immunologic | 1 | 2018 | 1 | 0.040 |
Why?
| | Acute Disease | 2 | 2014 | 77 | 0.040 |
Why?
| | Gastrointestinal Diseases | 1 | 2018 | 46 | 0.040 |
Why?
| | Physician-Patient Relations | 1 | 2017 | 17 | 0.040 |
Why?
| | Chaetomium | 1 | 2017 | 1 | 0.040 |
Why?
| | Mupirocin | 1 | 1996 | 3 | 0.040 |
Why?
| | Methicillin Resistance | 1 | 1996 | 3 | 0.040 |
Why?
| | Vacuum | 1 | 2016 | 1 | 0.040 |
Why?
| | Evaluation Studies as Topic | 1 | 1996 | 8 | 0.040 |
Why?
| | Cross Infection | 1 | 1996 | 12 | 0.040 |
Why?
| | Staphylococcus aureus | 1 | 1996 | 18 | 0.040 |
Why?
| | Staphylococcal Infections | 1 | 1996 | 21 | 0.040 |
Why?
| | DNA, Complementary | 1 | 1996 | 9 | 0.030 |
Why?
| | RNA | 1 | 1996 | 14 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 1996 | 36 | 0.030 |
Why?
| | Syndrome | 1 | 2016 | 34 | 0.030 |
Why?
| | Drug Administration Schedule | 1 | 1996 | 36 | 0.030 |
Why?
| | Genes, Bacterial | 1 | 2015 | 1 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 7 | 0.030 |
Why?
| | Protein Array Analysis | 1 | 2015 | 4 | 0.030 |
Why?
| | Microbiota | 1 | 2015 | 8 | 0.030 |
Why?
| | Phylogeny | 1 | 2015 | 23 | 0.030 |
Why?
| | Regression Analysis | 1 | 2015 | 52 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 1995 | 16 | 0.030 |
Why?
| | Forced Expiratory Volume | 2 | 1992 | 10 | 0.030 |
Why?
| | Cystic Fibrosis | 1 | 1995 | 20 | 0.030 |
Why?
| | Primary Health Care | 1 | 2015 | 41 | 0.030 |
Why?
| | Air Filters | 1 | 2014 | 1 | 0.030 |
Why?
| | Filtration | 1 | 2014 | 2 | 0.030 |
Why?
| | Astemizole | 1 | 1994 | 1 | 0.030 |
Why?
| | Premedication | 1 | 1994 | 2 | 0.030 |
Why?
| | Ranitidine | 1 | 1994 | 5 | 0.030 |
Why?
| | Odds Ratio | 1 | 2014 | 51 | 0.030 |
Why?
| | Immunization Schedule | 1 | 1994 | 10 | 0.030 |
Why?
| | Sulfides | 1 | 2014 | 6 | 0.030 |
Why?
| | Cyclopropanes | 1 | 2014 | 7 | 0.030 |
Why?
| | Acetates | 1 | 2014 | 5 | 0.030 |
Why?
| | Quinolines | 1 | 2014 | 6 | 0.030 |
Why?
| | Epitopes | 1 | 1993 | 20 | 0.030 |
Why?
| | Nasal Lavage Fluid | 1 | 1993 | 1 | 0.030 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2013 | 15 | 0.030 |
Why?
| | Horseradish Peroxidase | 1 | 1993 | 1 | 0.030 |
Why?
| | Adsorption | 1 | 1993 | 2 | 0.030 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 1993 | 1 | 0.030 |
Why?
| | Buffers | 1 | 1993 | 2 | 0.030 |
Why?
| | Protease Inhibitors | 1 | 1993 | 2 | 0.030 |
Why?
| | Indicators and Reagents | 1 | 1993 | 4 | 0.030 |
Why?
| | Arthropod Proteins | 1 | 2013 | 1 | 0.030 |
Why?
| | Cysteine Endopeptidases | 1 | 2013 | 2 | 0.030 |
Why?
| | Glycoside Hydrolases | 1 | 1993 | 2 | 0.030 |
Why?
| | Rabbits | 1 | 1993 | 6 | 0.030 |
Why?
| | Microbiological Techniques | 1 | 1993 | 5 | 0.030 |
Why?
| | Patient Care | 1 | 2013 | 6 | 0.030 |
Why?
| | Case-Control Studies | 1 | 2013 | 216 | 0.030 |
Why?
| | Respiratory Tract Infections | 1 | 2014 | 82 | 0.030 |
Why?
| | Meta-Analysis as Topic | 1 | 2012 | 14 | 0.030 |
Why?
| | Chest Pain | 1 | 1992 | 4 | 0.030 |
Why?
| | Hypersensitivity, Delayed | 1 | 1992 | 2 | 0.030 |
Why?
| | Maximal Expiratory Flow Rate | 1 | 1992 | 1 | 0.030 |
Why?
| | Theophylline | 1 | 1992 | 2 | 0.030 |
Why?
| | Beclomethasone | 1 | 1992 | 2 | 0.030 |
Why?
| | Vital Capacity | 1 | 1992 | 6 | 0.030 |
Why?
| | Cromolyn Sodium | 1 | 1992 | 3 | 0.030 |
Why?
| | Body Height | 1 | 1992 | 34 | 0.030 |
Why?
| | History, 20th Century | 1 | 1992 | 7 | 0.030 |
Why?
| | Canada | 1 | 1992 | 34 | 0.030 |
Why?
| | Body Weight | 1 | 1992 | 52 | 0.030 |
Why?
| | Chromatography | 1 | 1991 | 1 | 0.020 |
Why?
| | Sepharose | 1 | 1991 | 2 | 0.020 |
Why?
| | Phenols | 1 | 1991 | 7 | 0.020 |
Why?
| | Steroids | 1 | 2011 | 16 | 0.020 |
Why?
| | Europe | 1 | 2011 | 40 | 0.020 |
Why?
| | North America | 1 | 2011 | 43 | 0.020 |
Why?
| | Bronchial Spasm | 1 | 2010 | 1 | 0.020 |
Why?
| | Drug Therapy | 1 | 2010 | 7 | 0.020 |
Why?
| | Chromatography, Affinity | 1 | 1990 | 2 | 0.020 |
Why?
| | Michigan | 1 | 2010 | 2 | 0.020 |
Why?
| | Health Care Rationing | 1 | 2010 | 3 | 0.020 |
Why?
| | Patient Advocacy | 1 | 2010 | 5 | 0.020 |
Why?
| | Dysgammaglobulinemia | 1 | 1989 | 1 | 0.020 |
Why?
| | IgG Deficiency | 1 | 1989 | 1 | 0.020 |
Why?
| | Immunoglobulin M | 1 | 1989 | 5 | 0.020 |
Why?
| | Candida albicans | 1 | 1989 | 4 | 0.020 |
Why?
| | Drug Design | 1 | 2009 | 7 | 0.020 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2010 | 63 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2009 | 96 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2009 | 168 | 0.020 |
Why?
| | Partial Pressure | 1 | 1988 | 1 | 0.020 |
Why?
| | Pulse | 1 | 1988 | 1 | 0.020 |
Why?
| | Biological Assay | 1 | 1988 | 3 | 0.020 |
Why?
| | Respiration | 1 | 1988 | 5 | 0.020 |
Why?
| | Immunologic Tests | 1 | 2008 | 1 | 0.020 |
Why?
| | Dermatitis, Allergic Contact | 1 | 2008 | 1 | 0.020 |
Why?
| | Critical Care | 1 | 1988 | 12 | 0.020 |
Why?
| | Lung Diseases, Obstructive | 1 | 2008 | 3 | 0.020 |
Why?
| | Diagnostic Techniques and Procedures | 1 | 2008 | 5 | 0.020 |
Why?
| | Carbon Dioxide | 1 | 1988 | 16 | 0.020 |
Why?
| | Inflammation | 1 | 2008 | 49 | 0.020 |
Why?
| | Immunity, Cellular | 1 | 2008 | 18 | 0.020 |
Why?
| | Respiratory Syncytial Viruses | 1 | 1988 | 18 | 0.020 |
Why?
| | Cross Reactions | 1 | 2006 | 8 | 0.020 |
Why?
| | Spinal Puncture | 1 | 1985 | 1 | 0.020 |
Why?
| | Leukocyte Count | 1 | 1985 | 6 | 0.020 |
Why?
| | Monocytes | 1 | 1985 | 9 | 0.020 |
Why?
| | Child Abuse | 1 | 1986 | 47 | 0.020 |
Why?
| | Neutrophils | 1 | 1985 | 13 | 0.020 |
Why?
| | Seizures | 1 | 1985 | 24 | 0.020 |
Why?
| | Dermatitis, Irritant | 1 | 2004 | 1 | 0.020 |
Why?
| | Calcineurin Inhibitors | 1 | 2004 | 2 | 0.020 |
Why?
| | Phototherapy | 1 | 2004 | 2 | 0.020 |
Why?
| | Emollients | 1 | 2004 | 2 | 0.020 |
Why?
| | Skin Diseases, Infectious | 1 | 2004 | 2 | 0.020 |
Why?
| | Administration, Cutaneous | 1 | 2004 | 4 | 0.020 |
Why?
| | Anti-Inflammatory Agents | 1 | 2004 | 11 | 0.020 |
Why?
| | Hemodynamics | 1 | 2003 | 16 | 0.010 |
Why?
| | Electrocardiography | 1 | 2003 | 20 | 0.010 |
Why?
| | Therapeutic Equivalency | 1 | 2001 | 5 | 0.010 |
Why?
| | Suburban Population | 1 | 1999 | 1 | 0.010 |
Why?
| | Drug Resistance, Microbial | 1 | 1996 | 2 | 0.010 |
Why?
| | Infection Control | 1 | 1996 | 7 | 0.010 |
Why?
| | Physical Therapy Modalities | 1 | 1995 | 4 | 0.010 |
Why?
| | Fluid Therapy | 1 | 1995 | 19 | 0.010 |
Why?
| | Peak Expiratory Flow Rate | 1 | 1992 | 1 | 0.010 |
Why?
| | Incidence | 1 | 1992 | 134 | 0.010 |
Why?
|
|
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|